Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25704054 | 0.92 | CHRM2 (0.35) | CHRM2HRH4HRH3 | |
| SCHEMBL25569661 | 0.88 | CHRM2 (0.39) | CHRM2HRH4HRH3 | |
| SCHEMBL23695951 | 0.86 | PIK3CD (0.41) | CHRM2HRH4HRH3 | |
| SCHEMBL23567945 | 0.86 | PIK3CD (0.41) | CHRM2HRH4HRH3 | |
| SCHEMBL23696590 | 0.86 | PIK3CD (0.41) | CHRM2HRH4HRH3 | |
| SCHEMBL25566723 | 0.86 | CHRM2 (0.37) | CHRM2HRH4HRH3 | |
| SCHEMBL23806681 | 0.84 | PIK3CD (0.42) | HRH4HRH3 | |
| SCHEMBL8405817 | 0.83 | CHRM2 (0.48) | CHRM2KDM4CKDM4APHF8KDM2A | |
| SCHEMBL23945777 | 0.82 | SIGMAR1 (0.41) | CHRM2HRH4HRH3KDM4CKDM4A | |
| SCHEMBL25110753 | 0.81 | LMNA (0.43) | HRH4HRH3KDM4CKDM4APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | CHRM2 1946/4885HRH4 538/4885HRH3 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.